A-SEEDS

Pioneering non-viral CAR-T cell therapies for intractable cancers

Matsumoto, Japan · Founded 2020 · $15.0M raised

Headquarters
Matsumoto
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$15.0M
Last Round
$15.0M Series AJul 2025
Rounds
1

About

A-SEEDS Co., Ltd. is a Japanese clinical-stage biotech company spun out of Shinshu University in 2020, dedicated to developing non-viral gene-modified CAR-T cell therapies for intractable cancers. The company's proprietary PiggyBac transposon-based platform enables low-cost, scalable CAR-T cell manufacturing without viral vectors, targeting solid tumors including those expressing EPHB4 antigen. A-SEEDS completed the world's first human dosing of its AP8901 CAR-T product in 2025, has secured ¥2.38 billion in Series A funding, and is conducting multinational Phase I/Ib trials in Japan, the United States, and Australia.

Summary

A-SEEDS is a Biotech company based in Matsumoto, Japan, founded in 2020. It has raised $15.0M in total across 1 round, most recently a $15.0M Series A round in Jul 2025. Investors include Delight Ventures and Mizuho Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJul 2025
$15.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

A-SEEDS on Indexed.vc
<a href="https://indexed.vc/companies/a-seeds"><img src="https://indexed.vc/api/badge/company/a-seeds" alt="A-SEEDS on Indexed.vc" width="260" height="76" /></a>